2012
Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer
Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2012, 7: 188-195. PMID: 22134069, PMCID: PMC3253367, DOI: 10.1097/jto.0b013e318236ecbb.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiopsy, NeedleCarcinoma, Non-Small-Cell LungCohort StudiesComorbidityConfidence IntervalsGuideline AdherenceHumansLung NeoplasmsLymph NodesMediastinoscopyMediastinumMedicareMultivariate AnalysisNeoplasm StagingOdds RatioPositron-Emission TomographySEER ProgramSurvival AnalysisUnited StatesConceptsStage IIIA non-small cell lung cancerIIIA non-small cell lung cancerNon-small cell lung cancerInvasive stagingCell lung cancerMediastinal stagingLung cancerClinical stage IIIA non-small cell lung cancerEnd Results-Medicare databaseStage IIIA NSCLC patientsPositron emission tomography scanningPathologic lymph nodesIIIA NSCLC patientsMultivariable logistic regressionInvasive mediastinal stagingNSCLC patientsOlder patientsPatient characteristicsLymph nodesPatient factorsHistologic confirmationPractice patternsMedicare claimsMedicare beneficiariesPET scanning
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcome